Methotrexate Receives FDA Approval for Treatment of Rheumatoid Arthritis
Officials from the FDA have approved methotrexate (RediTrex, Cumberland Pharmaceuticals) as an injection for the treatment of adult and pediatric patients with rheumatoid arthritis.
Officials from the FDA have approved methotrexate (RediTrex, Cumberland Pharmaceuticals) as an injection for the treatment of adult and pediatric patients with rheumatoid arthritis. The injection is also indicated for adults with psoriasis, according to the company.
Methotrexate is approved as both an oral and injectable treatment in the United States. Injectable methotrexate has been shown to result in increased efficacy, greater continuation rates, and less discomfort for patients, while oral formulations are more widely available.
Cumberland, a specialty pharmaceutical company, will launch 2 injectable methotrexate product lines within the US, with both products intended for the treatment of active rheumatoid arthritis, juvenile idiopathic arthritis, and severe psoriasis.
Reference
Cumberland Pharmaceuticals receives FDA approval for RediTrex™ product line [news release]. Nashville, TN; Cumberland Pharmaceuticals: December 2, 2019. http://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-receives-fda-approval-reditrextm. Accessed December 3, 2019.
